Search

Your search keyword '"Hahn, Andrew W"' showing total 423 results
Start Over Author "Hahn, Andrew W"
423 results on '"Hahn, Andrew W"'

2. Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time among People with HIV in the Current Treatment Era

Author

Ma, Jimmy, Delaney, Joseph A. C., Ruderman, Stephanie A., Nance, Robin M., Hahn, Andrew W., Drumright, Lydia N., Whitney, Bridget M., Fredericksen, Rob J., Mixson, L. Sarah, Merrill, Joseph O., Safren, Steven A., Mayer, Kenneth H., O’Cleirigh, Conall, Napravnik, Sonia, Chander, Geetanjali, Moore, Richard D., Christopoulos, Katerina A., Willig, Amanda L., Bamford, Laura, Webel, Allison, McCaul, Mary E., Cachay, Edward R., Jacobson, Jeffrey M., Saag, Michael S., Kitahata, Mari M., Crane, Heidi M., and Williams, Emily C.

Published
2024
Full Text
View/download PDF

4. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance

Author

Gregg, Justin R., Newcomb, Lisa, Wu, Ranran, Dennison, Jennifer, Davis, John W., Pettaway, Curtis, Pisters, Louis, Ward, John F., Chapin, Brian F., Chéry, Lisly, Urkmez, Ahmet, Fang, Andrew M., Higgason, Noel, Troncoso, Patricia, Daniel, Carrie R., Logothetis, Christopher, Thompson, Timothy C., Hahn, Andrew W., Liu, Menghan, Zheng, Yingye, Lin, Dan W., Hanash, Samir, Irajizad, Ehsan, and Fahrmann, Johannes

Published
2024
Full Text
View/download PDF

5. Correction: Severity and Number of Substances Used are Independently Associated with Antiretroviral Therapy Adherence Over Time Among People with HIV in the Current Treatment Era

Author

Ma, Jimmy, Delaney, Joseph A. C., Ruderman, Stephanie A., Nance, Robin M., Hahn, Andrew W., Drumright, Lydia N., Whitney, Bridget M., Fredericksen, Rob J., Mixson, L. Sarah, Merrill, Joseph O., Safren, Steven A., Mayer, Kenneth H., O’Cleirigh, Conall, Napravnik, Sonia, Chander, Geetanjali, Moore, Richard D., Christopoulos, Katerina A., Willig, Amanda L., Bamford, Laura, Webel, Allison, McCaul, Mary E., Cachay, Edward R., Jacobson, Jeffrey M., Saag, Michael S., Kitahata, Mari M., Crane, Heidi M., and Williams, Emily C.

Published
2024
Full Text
View/download PDF

6. Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones

Author

Sakellakis, Minas J., Hahn, Andrew W., Ramachandran, Sumankalai, Zhang, Miao, Hoang, Anh, Song, Jian H., Liu, Jingjing, Wang, Feng, Basu, Hirak S., Sheperd, Peter, Wang, Xuemei, Frigo, Daniel E., Lin, Sue-Hwa, Panaretakis, Theocharis, Zhang, Jianhua, Navone, Nora, Troncoso, Patricia, Logothetis, Christopher J., and Titus, Mark A.

Published
2023
Full Text
View/download PDF

7. Drug and alcohol use among people living with HIV in care in the United States by geographic region

Author

Crane, Heidi M, Nance, Robin M, Whitney, Bridget M, Ruderman, Stephanie, Tsui, Judith I, Chander, Geetanjali, McCaul, Mary E, Lau, Bryan, Mayer, Kenneth H, Batey, D Scott, Safren, Steven A, Moore, Richard D, Eron, Joseph J, Napravnik, Sonia, Mathews, W Chris, Fredericksen, Rob J, Hahn, Andrew W, Mugavero, Michael J, Lober, William B, Saag, Michael S, Kitahata, Mari M, and Delaney, Joseph AC

Subjects
Clinical and Health Psychology, Health Sciences, Public Health, Human Society, Psychology, Sociology, Prevention, Substance Misuse, Methamphetamine, Brain Disorders, Alcoholism, Alcohol Use and Health, HIV/AIDS, Drug Abuse (NIDA only), Good Health and Well Being, Alcohol Drinking, Analgesics, Opioid, Crack Cocaine, HIV Infections, Humans, Practice Patterns, Physicians', United States, Drug use, alcohol use, marijuana, methamphetamine, HIV, Public Health and Health Services, Public health, Clinical and health psychology
Abstract

Substance use in the U.S. varies by geographic region. Opioid prescribing practices and marijuana, heroin, and methamphetamine availability are evolving differently across regions. We examined self-reported substance use among people living with HIV (PLWH) in care at seven sites from 2017-2019 to understand current regional substance use patterns. We calculated the percentage and standardized percentage of PLWH reporting current drug use and at-risk and binge alcohol use by U.S. Census Bureau geographic region and examined associations in adjusted logistic regression analyses. Among 7,686 PLWH, marijuana use was the most prevalent drug (30%), followed by methamphetamine/crystal (8%), cocaine/crack (7%), and illicit opioids (3%). One-third reported binge alcohol use (32%). Differences in percent of current use by region were seen for marijuana (24-41%) and methamphetamine/crystal (2-15%), with more use in the West and Northeast, and binge alcohol use (26-40%). In adjusted analyses, PLWH in the Midwest were significantly less likely to use methamphetamine/crystal (aOR: 0.13;0.06-0.25) or illicit opioids (aOR:0.16;0.05-0.53), and PLWH in the Northeast were more likely to use cocaine/crack (aOR:1.59;1.16-2.17), compared to PLWH in the West. Understanding differences in substance use patterns in the current era, as policies continue to evolve, will enable more targeted interventions in clinical settings among PLWH.

Published
2021

9. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

Author

Alhalabi, Omar, Groisberg, Roman, Zinner, Ralph, Hahn, Andrew W., Naing, Aung, Zhang, Shizhen, Tsimberidou, Apostolia M., Rodon, Jordi, Fu, Siqing, Yap, Timothy A., Hong, David S., Sun, Ming, Jiang, Yunfang, Pant, Shubham, Shah, Amishi Y., Zurita, Amado, Tannir, Nizar M., Vikram, Raghunandan, Roszik, Jason, Meric-Bernstam, Funda, and Subbiah, Vivek

Published
2023
Full Text
View/download PDF

10. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy

Author

Hahn, Andrew W., Kotecha, Ritesh R., Viscuse, Paul V., Pieretti, Alberto C., Wiele, Andrew J., Jonasch, Eric, Lee, Chung-Han, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Y., Campbell, Matthew T., Sharma, Padmanee, Motzer, Robert J., Russo, Paul, Wood, Christopher G., Tannir, Nizar M., Voss, Martin H., Karam, Jose A., Hakimi, A. Ari, and Msaouel, Pavlos

Published
2023
Full Text
View/download PDF

11. Validity Properties of a Self-reported Modified Frailty Phenotype Among People With HIV in Clinical Care in the United States

Author

Ruderman, Stephanie A., Webel, Allison R., Willig, Amanda L., Drumright, Lydia N., Fitzpatrick, Annette L., Odden, Michelle C., Cleveland, John D., Burkholder, Greer, Davey, Christine H., Fleming, Julia, Buford, Thomas W., Jones, Raymond, Nance, Robin M., Whitney, Bridget M., Mixson, L. Sarah, Hahn, Andrew W., Mayer, Kenneth H., Greene, Meredith, Saag, Michael S., Kamen, Charles, Pandya, Chintan, Lober, William B., Kitahata, Mari M., Crane, Paul K., Crane, Heidi M., and Delaney, Joseph A. C.

Published
2023
Full Text
View/download PDF

12. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Author

Alhalabi, Omar, Hahn, Andrew W., Msaouel, Pavlos, Meric-Bernstam, Funda, Wilson, Nathaniel, Naing, Aung, Piha-Paul, Sarina, Janku, Filip, Pant, Shubham, Yap, Timothy A, Hong, David S, Fu, Siqing, Karp, Daniel, Beltran, Kimberly, Campbell, Erick, Le, Hung, Campbell, Matthew T., Shah, Amishi, Tannir, Nizar M., Siefker-Radtke, Arlene, Gao, Jianjun, Roszik, Jason, and Subbiah, Vivek

Published
2022
Full Text
View/download PDF

15. Development of Frail RISC-HIV: a Risk Score for Predicting Frailty Risk in the Short-term for Care of People with HIV

Author

Ruderman, Stephanie A., Nance, Robin M., Drumright, Lydia N., Whitney, Bridget M., Hahn, Andrew W., Ma, Jimmy, Haidar, Lara, Eltonsy, Sherif, Mayer, Kenneth H., Eron, Joseph J., Greene, Meredith, Mathews, William C., Webel, Allison, Saag, Michael S., Willig, Amanda L., Kamen, Charles, McCaul, Mary, Chander, Geetanjali, Cachay, Edward, Lober, William B., Pandya, Chintan, Cartujano-Barrera, Francisco, Kritchevsky, Stephen B., Austad, Steven N., Landay, Alan, Kitahata, Mari M., Crane, Heidi M., and Delaney, Joseph A.C.

Published
2023
Full Text
View/download PDF

16. A phase II trial of apalutamide for intermediate‐risk prostate cancer and molecular correlates

Author

Hahn, Andrew W., primary, Manyam, Ganiraju C., additional, Chapin, Brian F., additional, Zhang, Miao, additional, Yu, Yao, additional, Pettaway, Curtis A., additional, Chery, Lisly, additional, Pisters, Louis L., additional, Ward, John F., additional, Gregg, Justin R., additional, Papadopoulos, John, additional, Kamat, Ashish M., additional, Lozano, Marisa, additional, Hoang, Anh, additional, Broom, Bradley, additional, Wang, Xuemei, additional, Huff, Chad D., additional, Logothetis, Christopher J., additional, Troncoso, Patricia, additional, Pilié, Patrick G., additional, and Davis, John W., additional

Published
2024
Full Text
View/download PDF

19. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.

Author

Johns, Andrew C, Campbell, Matthew T, Gao, Mamie, Hahn, Andrew W, Lim, Zita, Wang, Emily, Gao, Jianjun, Shah, Amishi Y, Msaouel, Pavlos, and Tannir, Nizar M

Subjects
MUCOSITIS, PATIENT safety, INTESTINAL perforation, RESEARCH funding, PROTEIN-tyrosine kinase inhibitors, HYPERTENSION, TREATMENT effectiveness, RETROSPECTIVE studies, FUNCTIONAL status, HEART failure, RENAL cell carcinoma, DRUG efficacy, MEDICAL records, ACQUISITION of data, PROGRESSION-free survival, DRUG tolerance, OVERALL survival, EVALUATION
Abstract

Background Tivozanib has been approved as a third-line or later therapy for advanced renal cell carcinoma based on the TIVO-3 trial, which was conducted before immune checkpoint therapies (ICT), cabozantinib, and lenvatinib/everolimus became incorporated in the current sequential treatment paradigm for advanced clear cell RCC (ccRCC). Methods We performed a retrospective study of patients with advanced ccRCC treated with tivozanib at MD Anderson Cancer Center during 6/2021-7/2023. A blinded radiologist assessed tumor response by RECIST v1.1. We assessed overall response rate (ORR), clinical benefit rate (CBR) [percentage of all treated patients who achieved radiologic response or stable disease (SD) for ≥ 6 months], progression-free survival (PFS), overall survival (OS), and safety. Results Of 30 analyzed patients, 23% had performance status ≥ 2; 47% had International Metastatic RCC Database Consortium (IMDC) poor-risk disease. Median number of prior therapies was 4 (range 1-8). All patients received prior ICT, 87% cabozantinib and 60% lenvatinib ± everolimus. Of 26 evaluable patients, 2 patients had confirmed partial response (ORR 7.7%); 5 patients had SD for ≥ 6 months (CBR 23.3%). Median PFS was 3.8 months (range 0.7-13.9); median OS was 14.1 months (range 0.3-28.5). Fifteen patients (50%) had ≥ 1 treatment-related adverse event (TRAE). There were 6 grade ≥ 3 TRAEs [hypertension, congestive heart failure (3), mucositis, and GI perforation (grade 5)]. Conclusions In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Supplementary Figure S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

23. Data from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

24. Supplementary Table S1 from Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., primary, Shore, Neal, primary, Agarwal, Neeraj, primary, Sieber, Paul, primary, Smith, Matthew R., primary, Dorff, Tanya, primary, Monk, Paul, primary, Rettig, Matthew, primary, Patel, Rupal, primary, Page, Anne, primary, Duff, Maureen, primary, Xu, Rongda, primary, Wang, Jian, primary, Barkund, Shravani, primary, Pankov, Aleksandr, primary, Wang, Amber, primary, Junttila, Melissa R., primary, Multani, Pratik S., primary, Daemen, Anneleen, primary, Chow Maneval, Edna, primary, Logothetis, Christopher J., primary, and Morris, Michael J., primary

Published
2024
Full Text
View/download PDF

25. VALIDATION OF A BLOOD-BASED SPHINGOLIPID PANEL FOR MEN WITH LOCALIZED PROSTATE CANCER ON ACTIVE SURVEILLANCE

Author

Gregg, Justin R., primary, Irajizad, Ehsan, additional, Wu, Ranran, additional, Dennison, Jennifer, additional, Davis, John W., additional, Pettaway, Curtis, additional, Pisters, Louis, additional, Ward, John F., additional, Chapin, Brian F., additional, Chery, Lisly, additional, Urkmez, Ahmet, additional, Troncoso, Patricia, additional, Daniel, Carrie, additional, Thompson, Timothy C., additional, Hahn, Andrew W., additional, Hanash, Samir, additional, Fahrmann, Johannes, additional, Liu, Menghan, additional, Newcomb, Lisa, additional, and Lin, Dan, additional

Published
2024
Full Text
View/download PDF

27. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Author

Abida, Wassim, primary, Hahn, Andrew W., additional, Shore, Neal, additional, Agarwal, Neeraj, additional, Sieber, Paul, additional, Smith, Matthew R., additional, Dorff, Tanya, additional, Monk, Paul, additional, Rettig, Matthew, additional, Patel, Rupal, additional, Page, Anne, additional, Duff, Maureen, additional, Xu, Rongda, additional, Wang, Jian, additional, Barkund, Shravani, additional, Pankov, Aleksandr, additional, Wang, Amber, additional, Junttila, Melissa R., additional, Multani, Pratik S., additional, Daemen, Anneleen, additional, Chow Maneval, Edna, additional, Logothetis, Christopher J., additional, and Morris, Michael J., additional

Published
2024
Full Text
View/download PDF

28. Evaluating the Sick Quitting Hypothesis for Frailty Status and Reducing Alcohol Use Among People With HIV in a Longitudinal Clinical Cohort Study

Author

Ruderman, Stephanie A., primary, Drumright, Lydia N., additional, Delaney, Joseph A. C., additional, Webel, Allison R., additional, Fitzpatrick, Annette L., additional, Whitney, Bridget M., additional, Nance, Robin M., additional, Hahn, Andrew W., additional, Ma, Jimmy, additional, Mixson, L. Sarah, additional, Eltonsy, Sherif, additional, Willig, Amanda L., additional, Mayer, Kenneth H., additional, Napravnik, Sonia, additional, Greene, Meredith, additional, McCaul, Mary, additional, Cachay, Edward, additional, Kritchevsky, Stephen B., additional, Austad, Steven N., additional, Landay, Alan, additional, Saag, Michael S., additional, Kitahata, Mari M., additional, Lau, Bryan, additional, Lesko, Catherine, additional, Chander, Geetanjali, additional, Crane, Heidi M., additional, and Odden, Michelle C., additional

Published
2024
Full Text
View/download PDF

30. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Author

Martínez Chanzá, Nieves, Xie, Wanling, Asim Bilen, Mehmet, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, and Harshman, Lauren C

Published
2019
Full Text
View/download PDF

32. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.

Author

Hahn, Andrew W, Surasi, Devaki Shilpa, Viscuse, Paul V, Bathala, Tharakeswara K, Wiele, Andrew J, Campbell, Matthew T, Zurita, Amado J, Shah, Amishi Y, Jonasch, Eric, Gao, Jianjun, Goswami, Sangeeta, Alhalabi, Omar, Rao, Priya, Sircar, Kanishka, Tannir, Nizar M, and Msaouel, Pavlos

Subjects
THERAPEUTIC use of antineoplastic agents, KIDNEY tumors, CANCER treatment, RISK assessment, SARCOMA, RESEARCH funding, CELL physiology, TREATMENT effectiveness, RETROSPECTIVE studies, MULTIVARIATE analysis, AMIDES, DESCRIPTIVE statistics, METASTASIS, IMMUNE checkpoint inhibitors, ODDS ratio, RENAL cell carcinoma, CANCER cells, CANCER patient psychology, CONFIDENCE intervals, DISEASE progression, SPECIALTY hospitals, OVERALL survival, EVALUATION
Abstract

Background Metastatic RCC with sarcomatoid and/or rhabdoid (S/R) dedifferentiation is an aggressive disease associated with improved response to immune checkpoint therapy (ICT). The outcomes of patients treated with VEGFR-targeted therapies (TT) following ICT progression have not been investigated. Patients and Methods Retrospective review of 57 patients with sarcomatoid (S), rhabdoid (R), or sarcomatoid plus rhabdoid (S + R) dedifferentiation who received any TT after progression on ICT at an academic cancer center. Clinical endpoints of interest included time on TT, overall survival (OS) from initiation of TT, and objective response rate (ORR) by RECIST version 1.1. Multivariable models adjusted for epithelial histology, IMDC risk, prior VEGFR TT, and inclusion of cabozantinib in the post-ICT TT regimen. Results 29/57 patients had S dedifferentiation and 19 had R dedifferentiation. The most frequently used TT was cabozantinib (43.9%) followed by selective VEGFR TT (22.8%). The median time on TT was 6.4 months for all, 6.1 months for those with S dedifferentiation, 15.6 months for R dedifferentiation, and 6.1 months for S + R dedifferentiation. Median OS from initiation of TT was 24.9 months for the entire cohort, and the ORR was 20.0%. Patients with R dedifferentiation had significantly longer time on TT than those with S dedifferentiation (HR 0.44, 95% CI, 0.21-0.94). IMDC risk was associated with OS. Conclusions A subset of patients with S/R dedifferentiation derive clinical benefit from TT after they have progressive disease on ICT. Patients with R dedifferentiation appeared to derive more benefit from TT than those with S dedifferentiation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. FIGURE 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

34. FIGURE 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

35. Data from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

36. FIGURE 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

37. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., additional, Song, Jian H., additional, Hoang, Anh, additional, Shepherd, Peter D. A., additional, Ramachandran, Sumankalai, additional, Navone, Nora M., additional, Efstathiou, Eleni, additional, Titus, Mark, additional, Corn, Paul G., additional, Lin, Sue-Hwa, additional, Logothetis, Christopher J., additional, and Panaretakis, Theocharis, additional

Published
2023
Full Text
View/download PDF

38. FIGURE 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

39. FIGURE 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 5 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

41. FIGURE 6 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 4 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 3 from Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Author

Gentile, Emanuela, primary, Hahn, Andrew W., primary, Song, Jian H., primary, Hoang, Anh, primary, Shepherd, Peter D. A., primary, Ramachandran, Sumankalai, primary, Navone, Nora M., primary, Efstathiou, Eleni, primary, Titus, Mark, primary, Corn, Paul G., primary, Lin, Sue-Hwa, primary, Logothetis, Christopher J., primary, and Panaretakis, Theocharis, primary

Published
2023
Full Text
View/download PDF

46. Venous thromboembolism among people with HIV: Design, implementation, and findings of a centralized adjudication system in clinical care sites across the United States

Author

Crane, Heidi M, primary, Nance, Robin M, additional, Ruderman, Stephanie A, additional, Haidar, Lara, additional, Tenforde, Mark W, additional, Heckbert, Susan R, additional, Budoff, Matthew J, additional, Hahn, Andrew W, additional, Drumright, Lydia N., additional, Ma, Jimmy, additional, Mixson, L. S., additional, Lober, William B, additional, Barnes, Gregory S, additional, McReynolds, Justin, additional, Attia, Engi F, additional, Peter, Inga, additional, Moges, Tesfaye, additional, Bamford, Laura, additional, Cachay, Edward, additional, Mathews, William C, additional, Christopolous, Katerina, additional, Hunt, Peter W, additional, Napravnik, Sonia, additional, Keruly, Jeanne, additional, Moore, Richard D, additional, Burkholder, Greer, additional, Willig, Amanda L, additional, Lindstrom, Sara, additional, Whitney, Bridget M, additional, Saag, Michael S, additional, Kitahata, Mari M, additional, Crothers, Kristina A, additional, and Delaney, Joseph AC, additional

Published
2023
Full Text
View/download PDF

48. Tobacco Smoking and Pack-Years Are Associated With Frailty Among People With HIV

Author

Ruderman, Stephanie A., primary, Odden, Michelle C, additional, Webel, Allison R., additional, Fitzpatrick, Annette L., additional, Crane, Paul K., additional, Nance, Robin M., additional, Drumright, Lydia N., additional, Whitney, Bridget M., additional, Mixson, Lyndsey Sarah, additional, Ma, Jimmy, additional, Willig, Amanda L., additional, Haidar, Lara, additional, Eltonsy, Sherif, additional, Mayer, Kenneth H., additional, O'Cleirigh, Conall, additional, Cropsey, Karen L., additional, Eron, Joseph J., additional, Napravnik, Sonia, additional, Greene, Meredith, additional, McCaul, Mary, additional, Chander, Geetanjali, additional, Cachay, Edward, additional, Lober, William B., additional, Kritchevsky, Stephen B., additional, Austad, Steven, additional, Landay, Alan, additional, Pandya, Chintan, additional, Cartujano-Barrera, Francisco, additional, Saag, Michael S., additional, Kamen, Charles, additional, Hahn, Andrew W., additional, Kitahata, Mari M., additional, Delaney, Joseph A. C., additional, and Crane, Heidi M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results